gefitinib has been researched along with resminostat in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (resminostat) | Trials (resminostat) | Recent Studies (post-2010) (resminostat) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 20 | 6 | 19 |
| Protein | Taxonomy | gefitinib (IC50) | resminostat (IC50) |
|---|---|---|---|
| Histone deacetylase 1 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.072 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, S; Fukuda, K; Konishi, H; Nishiyama, A; Ong, ST; Takagi, A; Takahashi, H; Takeuchi, S; Tanimoto, A; Yano, S | 1 |
1 other study(ies) available for gefitinib and resminostat
| Article | Year |
|---|---|
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
Topics: Apoptosis; Bcl-2-Like Protein 11; ErbB Receptors; Gefitinib; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; PC-3 Cells; Polymorphism, Genetic; Sulfonamides | 2020 |